More Articles

Patients and Medical

Could Data-Driven Chat Win HCPs' Hearts?

Adam Chapman, (Feb 20, 2018)

Evidence-based interactions have the potential to forge strong new ties with one of pharma's most crucial touchpoints: the HCP
Commercial

A Lesson In Leadership

Hugh Gosling, (Feb 16, 2018)

Helming an organization is a tall order, so what attributes separate the wheat from the chaff?
Access and Evidence

Raising The Curtain On Real-World Evidence

Danielle Barron, (Feb 13, 2018)

RWE continues to animate expectations far and wide, but its success calls for level-headed pragmatism
Patients and Medical

AstraZeneca: An Embarrassment Of Riches

Hugh Gosling, (Feb 7, 2018)

Medical Affairs has seen unprecedented growth in both size and scope in recent years, so new skills and capabilities are needed, says AZ’s Mark Mallon
Commercial

The New Normal

Adam Chapman, (Feb 3, 2018)

The pharma industry is on the cusp of a new dawn, but what does it look like?
Commercial

Build It And They Will Come

Hugh Gosling, (Feb 2, 2018)

“If the medicines are good, they’ll generate value”. It’s time to let the scientists lead the way, says AstraZeneca’s Mark Mallon
Patients and Medical

Clinical Trial Diversity: Vive La Différence

Hugh Gosling, (Jan 24, 2018)

Many companies are working hard to ensure their clinical trial populations match the diversity of the intended patient population, and Medical has a central role to play.
Commercial

When Science Fiction Becomes Science Fact

Hugh Gosling, (Jan 22, 2018)

With its strong heritage in collaboration and cutting-edge science, pharma is perfectly placed to embrace technology and deliver a new generation of interventions, says Bayer Chief Marketing Officer, Sebastian Guth.
Access and Evidence

Bridging The Evidence Gap

Danielle Barron, (Jan 15, 2018)

AstraZeneca's Head of Real World Evidence shares the story behind AZ's seminal RWE study and casts his projections on the future
Access and Evidence

Out With The OId, In With The New

Danielle Barron, (Jan 12, 2018)

Pharma must seek alternative pricing models if it is to become a greater dynamic force

Pages